Analyst Ratings For Momenta Pharmaceuticals (NASDAQ:MNTA)
Today, Stifel Nicolaus reiterated its Buy rating on Momenta Pharmaceuticals (NASDAQ:MNTA) with a price target of $26.00.
There are 1 sell rating, 4 hold ratings, 3 buy ratings on the stock.
The current consensus rating on Momenta Pharmaceuticals (NASDAQ:MNTA) is Hold (Score: 2.25) with a consensus target price of $17.00 per share, a potential 6.25% upside.
Some recent analyst ratings include
- 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 5/22/2017-Barclays PLC was Downgraded by analysts at Barclays PLC from a “Overweight ” rating to a ” Equal Weight” rating. They now have a $17.00 price target on the stock, up previously from $20.00 .
- 5/3/2017-Cowen and Company Reiterated Rating of Hold.
- 5/3/2017-Aegis Reiterated Rating of Hold.
- 2/21/2017-Leerink Swann was Downgraded by analysts at Leerink Swann from a “Outperform ” rating to a ” Market Perform” rating. They now have a $18.00 price target on the stock, up previously from $18.00 .
- 11/3/2016-J P Morgan Chase & Co Reiterated Rating of Buy.
Recent Insider Trading Activity For Momenta Pharmaceuticals (NASDAQ:MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) has insider ownership of 4.40% and institutional ownership of 86.62%.
- On 5/22/2017 Bruce Leicher, SVP, sold 859 with an average share price of $14.80 per share and the total transaction amounting to $12,713.20. View SEC Filing
- On 5/19/2017 Craig A Wheeler, President, sold 4,116 with an average share price of $15.83 per share and the total transaction amounting to $65,156.28. View SEC Filing
- On 5/19/2017 Ganesh Venkataraman Kaundinya, VP, sold 821 with an average share price of $15.90 per share and the total transaction amounting to $13,053.90. View SEC Filing
- On 5/10/2017 Bruce Leicher, SVP, sold 347 with an average share price of $16.00 per share and the total transaction amounting to $5,552.00. View SEC Filing
- On 5/10/2017 Craig A. Wheeler, President, sold 1,852 with an average share price of $15.77 per share and the total transaction amounting to $29,206.04. View SEC Filing
- On 5/10/2017 Ganesh Venkataraman Kaundinya, VP, sold 384 with an average share price of $16.00 per share and the total transaction amounting to $6,144.00. View SEC Filing
- On 12/15/2016 Richard P Shea, CFO, sold 9,799 with an average share price of $15.00 per share and the total transaction amounting to $146,985.00. View SEC Filing
Recent Trading Activity for Momenta Pharmaceuticals (NASDAQ:MNTA)
Shares of Momenta Pharmaceuticals closed the previous trading session at 16.00 down -0.55 -3.32% with 957,572 shares trading hands.